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chorych (45,6 %) i liB - 37 chorych (36,6%). Rozpoznanie przedstawialo si~ nast~pujqCo: LP - 4
chorych (3,9%), NS 1- 53 chorych - (52,8%), NSII - 29 chorych (28,7%) i Me - 15 chorych (14,6%).
Metoda: Chemioterapi~ prowadzono typowo wg schematu MOPP/ABV. Podano srednio 5 kurs6w
leczenia (44 chorych - 4 kursy. 2 chorych - 5 kurs6w, 55 chorych - 6 kurs6w). Uzupetniajqco leczono
chorych napromienianiem (IF - 66 chorych, "Mantel" - 19 chorych, STNI - 14 chorych, Y - 2 chorych)
spozytkowujqc wiqzki promieniowania Gamma Co - 60 foton6w X 0 energiach: 4,9 lub 15 MeV dawkq
frakcyjnq 1,8 - 2,0 Gy/t do dawki calkowitej 36-40 cGy/t.
Wyniki: Obserwowane przezycia catkowite wynoszq od 14-62 miesi~cy (srednio 30,3 miesiqca)
a przezycia wolne od choroby od 2 do 51 miesi~cy (srednio 20,7 miesiqca). W analizowanej grupie
zmarlo 2 chorych z powodu progresji ziarnicy, u 10 stwierdzono nawrot w czasie 4-13 miesi~cy
po leczeniu. Obecnie w trakcie leczenia 2-go rzutu znajduje si~ 2 chorych a 4 znajduje si~ obecnie
po chemioterapii 2 -go rzutu i przeszczepie kom6rek macierzystych szpiku - pozostajet w obserwacji








W STOPNIU ZAAWANSOWANIA I-iliA.
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Klinika Nowotworow Uktadu Chtonnego Centrum Onkologii - Instytutu w Warszawie
W latach 1978-1993, w Klinice Radioterapii Centrum Onkologii w Warszawie, leczono 258 chorych
na ziarnic~ ztosliwq w stopniu zaawansowania klinicznego I-lilA. 84 chorych (40 kobiet i 44 m~zczyzn)
zakwalifikowano do leczenia skojarzonego, chemicznego 6 kursami wg programu MOPP
z uzupelniajqcym napromienianiem. Sredni wiek chorych wynosi131 lat, przewazali chorzy: w wieku
ponizej 20 roku zycia (32%) - z typem histologicznym ziarnicy NS I (49%), w II stopniu
zaawansowania klinicznego (liB - 46%, IIA - 33 %).
Zastosowano uzupelniajetce napromienianie na pola: wydzielone u 48, ptaszczowe gorne - 26,
plaszczowe dolne - 2, STNI - 6, TNI - 2 chorych.
Wst~pnie okreslone odsetki prawdopodobienstwa 5 letl1iego przezycia calkowitego i wolnego
od nawrotu choroby wynosily odpowiednio: 86 i 81 %. Obserwowany sredni czas przezycia
calkowitego wynios176,4 miesiqca (20-116 miesil~cy) natomiast przezycia wolnego od choroby - 64,8
miesietca (6-115 miesi~cy). Przedstawione b~dq szczeg610wo wyniki i powiklania stosowanego
leczenia.
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TOWARDS A NEW LEGAL FRAMEWORK FOR RADIOTHERAPY IN
THE EU MEMBER STATES: IS THERE A SCOPE FOR
HARMONISATION? CAN ESTRO CONTRIBUTE?
Germaine Heeren
Public Relations Officer, ESTRO Office
On 30 June 2997 the official journal of the European Communities published the "Council Directive
97143/Euratom on health protection of individuals against the dangers of ionising radiation in relation
to medical exposure and repealing Directive 84/466/Euratom". Since radiation protection issues are
generally not the concern and responsibility of the clinical radiotherapy community, this directive
escaped attention until ESTRO was invited to contribute to a conference scheduled from 28 to 30 April
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of this year in Luxembourg, on the transposition af the directive into national law, a requirement the
member states have to comply with before 13 May 2000.
A quick analysis of the text revealed that, in the context of this directive, the term radiation protection
needed to be interpreted in the broadest possible sense: not only the physical conditions preventing
occupational hazards and environmental contamination, but the protection of the patient against
undue exposure and, as far as radiotherapy is concerned: the delivery of the appropriate dose to the
patient. The directive touches upon format education and training requirements, accreditation of
individuals and departments, minimal infrastructural requirements, staffing, recommendations for
continued medical education and the implementation of quality assurance measures.
Is the European Radiation Oncology ready for this? Did we do our homework?
Whereas some other medical associations were pressing for European examinations and diplomas
ESTRO has chosen for bottom-up approach by patiently and carefully working at a grassroots level on
a convergence of European standards through its quality assurance, education, exchange and
mobility programmes. Besides, the newly created European Board of Radiotherapy in which the
scientific community (ESTRO) and the professional bodies (UEMS) are represented on a parity basis,
started tackling the issues the profession needs to face up to in order to provide a solid basis for the
guaranteed freedom of movement of its members within the European space: the harmonisation of
basic and continued education, guidelines for the length and content of the practical training in
radiotherapy (logbook system), and minimum standards for the accreditation of teaching departments.
A European examination and diploma were only envisaged to come at the end of the road. However,
with the European directive in mind these long term objectives have now gained momentum and. If
ESTRO is to playa role in building a European consensus around the legal framework which will
govern the future functioning of Radiation Oncology in Europe, it will have to come up quickly with
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Introduction
The potential of systemic irradiation for the treatment of disseminated malignant disease was
recognised almost immediately after the discovery of radioactivity by Madame Curie in 1897. By 1905,
a German physicist, Frederick Dessauer, had designed an arrangement of x-ray sources, which would
give a homogeneous dose of irradiation to the whole body. The treatment of 3 patients with leukaemia
was reported by Adalar Eifer in a Hungarian journal in 1907. In 1923, Chaoul & Lange from the
University Clinic of Surgery in Munich treated 12 patients with Hodgkin's disease, of whom 8 showed
responses which lasted at least 7 months (1).
Special equipment for total body irradiation was installed at the Memorial Hospital, New York, in May
1931 and by June of the next year, Heublein reported results with 185 KV x-rays given at a dose rate
of 0,67 to 1,26 cGy per hour to patients at distance of 18-14 feet (5.5-7.5 meters). He concluded that
the safe whole body dose was 25% of an erythema dose (7.5 Gy measured in air) and noticed
"encouraging improvement" in 3 out of 10 patients, but rio pronounced "beneficial clinical
manifestations: (2). Nevertheless, this work continued and in 1942, an analysis of 270 patients was
presented by Medinger and Craver (3).
Doses were limited to 3 Gy because of haematological toxicity and research soon started to find
ways of overcoming this limitation. Thomas et al. (4) reported the use of intravenous infusion of bone
marrow to patients receiving radiation and chemotherapy. The discovery of leuco-agglutinating
antibodies by Dausset (5) stimulated much research, which led to the recognition of leukocyte
histocompatibility antigens. An understating of these was essential for the initial development of safe
bone marrow transplantation (BMT), which removed the dose limiting toxicity of total body irradiation
(TBI) and permitted the use of much higher doses. Increasing experience has led to better ways of
preventing graft versus host disease (GvHD) and enabled rescue after high dose therapy to be
extended to the majority who do not have compatible sibling. (6)
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